Loading...
Halozyme Therapeutics

Project Description

CEO: Helen Torley, M.B. Ch. B., M.R.C.P.
Headquarters: San Diego, California
URL: www.halozyme.com
Investment Date: January 2004
APO Financing: $8.1 Million
Trading Venue: NASDAQ GS (HALO)

Halozyme Therapeutics is a biotechnology company focused on developing and commercializing novel oncology therapies that target the tumor microenvironment. Halozyme’s lead proprietary program, our investigational drug PEGPH20, applies a unique approach to targeting solid tumors, allowing increased access of co-administered cancer drug therapies to the tumor. PEGPH20 is currently in development for metastatic pancreatic cancer and non-small cell lung cancer and has potential across additional cancers in combination with different types of cancer therapies.

In addition to its proprietary product portfolio, Halozyme has established value-driving partnerships with leading pharmaceutical companies including Roche, Pfizer, Janssen and Baxter for its drug delivery platform, ENHANZE™, which enables biologics and small molecule compounds that are currently administered intravenously to be delivered subcutaneously. Halozyme is headquartered in San Diego, CA.

COMPANIES WE HAVE FUNDED